Skip to content

AVALO THERAPEUTICS, INC.: 10-Q filed 2018-08-09

What AVALO THERAPEUTICS, INC. reported in its quarterly report filed 2018-08-09 (fiscal Q2 2018): 39 published measures, 99 facts as tagged in accession 0001628280-18-010858.

This filing

Form
10-Q (quarterly report)
Filed
2018-08-09
Fiscal period
fiscal Q2 2018
Accession
0001628280-18-010858 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AVALO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-06-3062,145,214USD
At 2017-12-3142,806,907USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-06-3042,925,797USD
At 2017-12-3114,947,299USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-06-3019,219,417USD
At 2017-12-3127,859,608USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-06-302,179,775USD
At 2017-12-312,472,187USD
At 2017-06-305,460,699USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-6,007,476USD91
2018-01-01 to 2018-06-30-9,890,319USD181
2017-04-01 to 2017-06-30-1,798,515USD91
2017-01-01 to 2017-06-30-3,759,152USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-614,096USD181
2017-01-01 to 2017-06-30-3,995,518USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-01-01 to 2018-06-3025,931USD181
2017-01-01 to 2017-06-301,801USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2018-04-01 to 2018-06-304,785,138USD91
2018-01-01 to 2018-06-309,267,913USD181
2017-04-01 to 2017-06-30157,800USD91
2017-01-01 to 2017-06-30542,006USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-06-30398,873USD181
2017-01-01 to 2017-06-304,332,262USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-25,932USD181
2017-01-01 to 2017-06-30-1,801USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-06-30-68,055,579USD
At 2017-12-31-58,165,260USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-04-01 to 2018-06-3016,351USD91
2018-01-01 to 2018-06-3039,664USD181
2017-04-01 to 2017-06-300USD91
2017-01-01 to 2017-06-300USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-06-3058,417USD
At 2017-12-3144,612USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-06-30851,255USD181
2017-01-01 to 2017-06-30587,963USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-5,739,397USD91
2018-01-01 to 2018-06-30-9,231,159USD181
2017-04-01 to 2017-06-30-1,774,995USD91
2017-01-01 to 2017-06-30-3,674,123USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-06-3011,838,311USD
At 2017-12-3110,674,180USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-06-3019,045,320USD
At 2017-12-3111,089,250USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-06-302,939,939USD
At 2017-12-311,298,980USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2018-06-3018,070,283USD
At 2017-12-3114,292,282USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-04-01 to 2018-06-3010,524,535USD91
2018-01-01 to 2018-06-3018,499,072USD181
2017-04-01 to 2017-06-301,932,795USD91
2017-01-01 to 2017-06-304,216,129USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2018-06-301,540,534USD
At 2017-12-31382,153USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-04-01 to 2018-06-301,082,698USD91
2018-01-01 to 2018-06-302,732,475USD181
2017-04-01 to 2017-06-30493,649USD91
2017-01-01 to 2017-06-301,446,719USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-06-3033,790,686shares
At 2017-12-3131,266,989shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2018-06-302,364,344USD
At 2017-12-312,605,499USD
At 2017-06-305,536,840USD
At 2016-12-315,201,897USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-06-3087,241,204USD
At 2017-12-3183,338,136USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2018-06-3032,003,161USD
At 2017-12-3117,664,480USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-06-300USD
At 2017-12-3124,272USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-06-30954,454USD
At 2017-12-31703,225USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2018-06-30819,375USD
At 2017-12-310USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2018-06-3030,908USD
At 2017-12-317,144USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-303,041,955USD91
2018-01-01 to 2018-06-305,949,318USD181
2017-04-01 to 2017-06-301,439,146USD91
2017-01-01 to 2017-06-302,769,410USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2018-01-01 to 2018-06-302,262,570USD181
2017-01-01 to 2017-06-3011,689USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2018-04-01 to 2018-06-301,233,035USD91
2018-01-01 to 2018-06-302,250,444USD181
2017-04-01 to 2017-06-300USD91
2017-01-01 to 2017-06-300USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-251,728USD91
2018-01-01 to 2018-06-30-619,496USD181
2017-04-01 to 2017-06-30-23,520USD91
2017-01-01 to 2017-06-30-85,029USD181

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2018-01-01 to 2018-06-3023,764USD181
2017-01-01 to 2017-06-300USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-01-01 to 2018-06-300USD181
2017-01-01 to 2017-06-301,693,498USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-06-30373,299USD181
2017-01-01 to 2017-06-300USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-06-30617,619USD181
2017-01-01 to 2017-06-300USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-06-301,640,959USD181
2017-01-01 to 2017-06-30-682,907USD181

Inspect the source

Entity
AVALO THERAPEUTICS, INC. / CIK 0001534120
Captured
2026-09-20T09:16:35.394Z
SEC response SHA-256
c27cef5388033067af62e0489a1b2af90f086713b680df0f63e0f63ad2ea1ca3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001534120.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))